News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Pharmalucence, Inc. Announces FDA Approval for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Breast Cancer Patients
July 25, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BEDFORD, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Lung cancer
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss
October 21, 2025
·
2 min read
·
Tristan Manalac
Autoimmune disease
Roche’s Gazyva Expands Out of Cancer With FDA Approval for Lupus
October 20, 2025
·
2 min read
·
Dan Samorodnitsky
FDA
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug
October 20, 2025
·
2 min read
·
Heather McKenzie
Approvals
Novo Secures Cardiovascular Expansion for Semaglutide Pill
October 20, 2025
·
2 min read
·
Tristan Manalac